ERBB2 and breast cancer: The median age at diagnosis of HER2+ AR+ BC patients were 59 years (p: 0.045) and showed the following features: histological grade 2 was found in 17.3% of AR+ tumors vs. 5.2% of AR− tumors (p: 0.020), pT1 in 33.7% of AR+ tumors vs. 20.8% of AR− ones (p: 0.020), prognostic stage I in 42.8% AR+ BC vs. 16.3% of those with AR negativity (p: 0.001).